Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Corrigendum to 'Patient-related characteristics considered to affect patient involvement in shared decision making about treatment: A scoping review of the qualitative literature' Patient Education and Counseling 111 (2023) 107677.

Autor: Keij SM; Medical Decision Making, Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands. Electronic address: s.m.keij@lumc.nl., Lie HC; Department of Behavioural Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Norway., Laidsaar-Powell R; Centre for Medical Psychology and Evidence-Based Decision-Making (CeMPED), School of Psychology, The University of Sydney, Sydney, NSW, Australia., Kunneman M; Medical Decision Making, Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands; Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA., de Boer JE; Medical Decision Making, Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands., Moaddine S; Medical Decision Making, Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands., Stiggelbout AM; Medical Decision Making, Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands., Pieterse AH; Medical Decision Making, Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands.

Publikováno v: Patient education and counseling [Patient Educ Couns] 2024 Jul; Vol. 124, pp. 108257. Date of Electronic Publication: 2024 Mar 26.

How are patient-related characteristics associated with shared decision-making about treatment? A scoping review of quantitative studies.

Autor: Keij SM; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., de Boer JE; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Stiggelbout AM; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Bruine de Bruin W; Schaeffer Center for Health Policy and Economics, Dornsife Department of Psychology, and Price School of Public Policy, University of Southern California, Los Angeles, California, USA., Peters E; Center for Science Communication Research, School of Journalism and Communication, University of Oregon, Eugene, Oregon, USA., Moaddine S; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Kunneman M; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.; Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA., Pieterse AH; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands pieterse@lumc.nl.

Publikováno v: BMJ open [BMJ Open] 2022 May 24; Vol. 12 (5), pp. e057293. Date of Electronic Publication: 2022 May 24.

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.

Autor: Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., van Waalwijk van Doorn-Khosrovani SB; CZ Health Insurance, Tilburg, Netherlands., van Roy AAMGP; CZ Health Insurance, Tilburg, Netherlands., Timmers L; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., Ly Tran TH; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., de Boer JE; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., de Wit GF; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands., Blijlevens N; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands., Wymenga ANM; Department of Medical Oncology, Medical Spectrum Twente, Enschede, Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands. Electronic address: e.voest@nki.nl.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2022 Feb; Vol. 23 (2), pp. 198-201.

[Pharmacotherapeutic compass 1998].

Autor: van Oppenraay ML; Centrale Medisch Pharmaceutische Commissie, Amstelveen., van der Beek CM, de Boer JE, Danz M, Schutte MK, Verduijn JP

Publikováno v: Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 1998 Mar 21; Vol. 142 (12), pp. 633-6.